Abstract:the of in various serotypes a the capsid internal that determine the internal of 22 eukaryotic viruses with icosahedral symmetry including that belong to the family of Parvoviridae. In addition, we the maximal packaging capacity of both capsids and VP3 only capsids from various serotypes using a of recombinant AAV2 vector genomes of varying sizes from 4.80 kb up to 6.00 kb by an increment of 0.05 kb, ruler genomes. determine capsid internal volumes, three dimensional structure coordinates of each viral capsid were from the Protein Data Bank, and an we each a interstices between adjacent atoms in the protein are effectively filled the of the inner surface of the capsid The of capsid a numerical integration of in the to the center than the atom that is most distant from the center of the capsid. By this method, we find that the genome lengths and internal volumes of the 22 eukaryotic T=1 viruses that we analyzed vary from 0.83 kb to 6.04 kb and from 6.72 x 10 5 to 3.46 x 10 6 Å 3 , respectively, showing a strong non-linear allometric relationship with an exponent of 1.30 (R 2 =0.97). In the following AAV serotypes, AAV1, 2, 3B, 4, 5, 6, 8 and 9, AAV5 is found to have a distinctively smaller volume (2.48 x 10 6 Å 3 ) compared to the other 7 serotypes (2.62 ± 0.03 x 10 6 Å 3 , mean ± SD). This analysis also reveals that AAV2 VP3 only capsid has a 7% larger volume than AAV2 VP1/VP2/VP3 capsid. In keeping with this observation, a preliminary study using the ruler genomes has indicated that the AAV2 VP3 capsid can package a genome that is longer than that can be packaged in the AAV2 VP1/VP2/VP3 capsid by several hundred nucleotides, which appears to correspond to the difference in the volume of the two different capsids. Investigation of other serotypes and capsid mutants is currently underway. Thus, the approach presented here will help understand the genome packaging and provide insights into how to design capsids to overcome packaging limitations. Vector dose-related toxicity has been highlighted as a potential safety concern in recent preclinical studies and clinical trials with recombinant AAV vectors. Thus, investigation of strategies to enhance AAV transduction may allow for administration of lower vector doses, thereby mitigating toxicity. Several host cell factors have been shown to restrict viral infection during post-entry trafficking steps through a variety of mechanisms. the overexpression of ERI-1 determined an over 10-fold, selective reduction on ssAAV genome association with H3 and H4, while changes were negligible for scAAV DNA and for control cellular genes. Consistent with chromatin exerting a repressive role on ssAAV transduction, we also noticed downregulation of replication-dependent chaperone induced over in transduction. decreased findings be development effective delivery strategies. of hepatic transgene product. Our suggest and reinforce the importance of Kupffer cells as key APCs for hepatic antigens and further characterize the impact of the route of antigen expression on T cell activation and Treg induction.

E2A, VA RNA I and L4-22k adenoviral helper genes are sufficient for AAV production in HEK293 cells

Molecular design of controllable recombinant adeno‐associated virus (AAV) expression systems for enhanced vector production

AAV production in stable packaging cells requires expression of adenovirus 22/33K protein to allow episomal amplification of integrated rep/cap genes

Process Improvement of Adeno-Associated Virus Production

Identification of Broadly Applicable Adeno-Associated Virus Vectors by Systematic Comparison of Commonly Used Capsid Variants In Vitro

Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination

Enhancing the production of adeno‐associated virus (AAV)2 and AAV9 with high full capsid ratio in HEK293 cells through design‐of‐experiment optimization of triple plasmid ratio

High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle Virus

558. Second Generation Vaccinia Carrier for Scalable and Efficient Production of Recombinant AAV Vectors

Proteomic Landscape of Adeno-Associated Virus (AAV)-Producing HEK293 Cells

AAV Biology 37. Capacity of Viral Genome Packaging and Internal Volumes of AAV Viral Particles Trafficking as a Strategy to Enhance Recombinant AAV Transduction

High‐yield recombinant adeno‐associated viral vector production by multivariate optimization of bioprocess and transfection conditions

Advanced biomanufacturing and evaluation of adeno-associated virus

Rep/Cap Gene Amplification and High-Yield Production of AAV in an A549 Cell Line Expressing Rep/Cap.

Establishment of a High-Yield Recombinant Adeno-Associated Virus/Human Bocavirus Vector Production System Independent of Bocavirus Nonstructural Proteins

High-Level rAAV Vector Production by rAdV-Mediated Amplification of Small Amounts of Input Vector

Enhanced ER protein processing gene expression increases rAAV yield and full capsid ratio in HEK293 cells

Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing.

Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells

A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors.

Tuning capsid formation dynamics in recombinant adeno‐associated virus producing synthetic cell lines to enhance full particle productivity